Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck

doi:10.5306/wjco.v6.i5.166

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6134)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

364

WORD

259

HTML

2500

Figures (1-2)

206

Tables (1-3)

171

Sum=3500

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

988

Download

1646

Sum=2634

Oct 10, 2015 (publication date) through Aug 31, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Clin Oncol. Oct 10, 2015; 6(5): 166-173
Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.166

Open in New Tab Full Size Figure Download Figure

Figure 1 Overall and progression-free survival.

Open in New Tab Full Size Figure Download Figure

Figure 2 Mean (± SE) trough selenium concentrations in plasma prior to selenomethionine, after 1 and 2 wk of selenomethionine intake, and 1-2 wk after the end of treatment. SLM: Selenomethionine; Se: Selenium.

Citation: Mix M, Singh AK, Tills M, Dibaj S, Groman A, Jaggernauth W, Rustum Y, Jameson MB. Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck. World J Clin Oncol 2015; 6(5): 166-173
URL: https://www.wjgnet.com/2218-4333/full/v6/i5/166.htm
DOI: https://dx.doi.org/10.5306/wjco.v6.i5.166